Study identifier:SD-039-0725
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A 12 week, Randomized, Double-Blind, Double-Dummy, Active-Controlled study of SYMBICORT pMDI Administered Once Daily in children and adolescents 6 to 15 years of age with asthma - SPROUT
asthma
Phase 3
No
budesonide/formoterol (Symbicort), budesonide
All
540
Interventional
6 Years - 15 Years
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The purpose of this study is to compare Symbicort with budesonide alone for the treatment of asthma in children aged 6 to 15 years
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: 1 budesonide/formoterol | - |
Active Comparator: 2 budesonide | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.